Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitogen-activated protein kinase kinase kinase 12 (MAP3K12), also known as Dual leucine zipper kinase (DLK), is a serine/threonine-protein kinase predominantly expressed in neurons. It is a critical upstream regulator of kinase cascades that mediate responses to cellular stress, axonal injury, and neuronal development. MAP3K12 activates the MAPK/JNK pathway by phosphorylating and activating MKK7, leading to downstream activation of c-Jun and other transcription factors, ultimately regulating processes such as axon growth, neuronal migration, apoptosis, and axonal degeneration. DLK plays key roles in nervous system development, injury responses, neurodegeneration, and regeneration, and is considered an emerging therapeutic target for neurodegenerative disorders. Selective inhibition of MAP3K12/DLK is neuroprotective in experimental models, but safety concerns remain due to its roles in normal neuronal function and development.
Inhibition of MAP3K12/DLK reduces phosphorylation of MKK7 and JNK, blocking pro-apoptotic and degenerative signaling in neurons, thereby providing neuroprotection
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitogen-activated protein kinase kinase kinase 12 (MAP3K12).